
Suzanne V Arnold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8792553/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. Journal of the American College of Cardiology, 2018, 71, 2628-2639.	2.8	370
2	Interpreting the Kansas City Cardiomyopathy Questionnaire in ClinicalÂTrials and Clinical Care. Journal of the American College of Cardiology, 2020, 76, 2379-2390.	2.8	224
3	Predictors of Poor Outcomes After Transcatheter Aortic Valve Replacement. Circulation, 2014, 129, 2682-2690.	1.6	214
4	Relation of Frailty to Outcomes After Transcatheter Aortic Valve Replacement (from the PARTNER) Tj ETQq0 0 0 r	gBT /Over 1.6	lock 10 Tf 50

5	Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina. Journal of the American College of Cardiology, 2013, 61, 2038-2045.	2.8	184
6	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e779-e806.	1.6	157
7	Preoperative Anxiety as a Predictor of Mortality and Major Morbidity in Patients Aged >70 Years Undergoing Cardiac Surgery. American Journal of Cardiology, 2013, 111, 137-142.	1.6	148
8	Perceived Stress in Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1756-1763.	2.8	141
9	Use of the Kansas City Cardiomyopathy Questionnaire for Monitoring Health Status in Patients With Aortic Stenosis. Circulation: Heart Failure, 2013, 6, 61-67.	3.9	137
10	Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. Circulation: Heart Failure, 2013, 6, 1139-1146.	3.9	130
11	Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 1868-1877.	2.8	128
12	Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiology, 2017, 2, 1315.	6.1	126
13	Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH). Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 467-476.	2.2	115
14	Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population. JAMA Cardiology, 2017, 2, 409.	6.1	110
15	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project. European Journal of Preventive Cardiology, 2017, 24, 1637-1645.	1.8	109
16	Economic Impact of Angina After an Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 344-353.	2.2	107
17	Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. JAMA Cardiology, 2017, 2, 837.	6.1	105
18	Beyond Medication Prescription as Performance Measures. Journal of the American College of Cardiology, 2013, 62, 1791-1801.	2.8	102

#	Article	IF	CITATIONS
19	Health Status After Transcatheter orÂSurgical Aortic Valve Replacement inÂPatients With Severe Aortic Stenosis atÂlncreased Surgical Risk. JACC: Cardiovascular Interventions, 2015, 8, 1207-1217.	2.9	100
20	Impact of Ejection Fraction and AorticÂValve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 67, 2349-2358.	2.8	97
21	How to Define a Poor Outcome After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 591-597.	2.2	96
22	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation, 2019, 140, 618-620.	1.6	96
23	Health Status After Transcatheter Mitral-Valve Repair in Heart FailureÂandÂSecondary MitralÂRegurgitation. Journal of the American College of Cardiology, 2019, 73, 2123-2132.	2.8	94
24	Converting the Informed Consent From a Perfunctory Process to an Evidence-Based Foundation for Patient Decision Making. Circulation: Cardiovascular Quality and Outcomes, 2008, 1, 21-28.	2.2	83
25	Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 844-850.	2.2	81
26	Should Transcatheter Aortic Valve Replacement Be Performed in Nonagenarians?. Journal of the American College of Cardiology, 2016, 67, 1387-1395.	2.8	79
27	Costs of Periprocedural Complications in Patients Treated With Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2014, 7, 829-836.	3.9	76
28	Health Status After Transcatheter AorticÂValve Replacement in PatientsÂatÂExtreme Surgical Risk. JACC: Cardiovascular Interventions, 2015, 8, 315-323.	2.9	76
29	Impact of Short-Term Complications on Mortality and Quality of Life After TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 362-369.	2.9	74
30	Relation Between Six-Minute Walk Test Performance and Outcomes After Transcatheter Aortic Valve Implantation (from the PARTNER Trial). American Journal of Cardiology, 2013, 112, 700-706.	1.6	70
31	Statin Use in Outpatients With Obstructive Coronary Artery Disease. Circulation, 2011, 124, 2405-2410.	1.6	62
32	Patterns of Statin Initiation, Intensification, and Maximization Among Patients Hospitalized With an Acute Myocardial Infarction. Circulation, 2014, 129, 1303-1309.	1.6	62
33	Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Diabetes and Severe Aortic Stenosis at High Risk for Surgery. Journal of the American College of Cardiology, 2014, 63, 1090-1099.	2.8	61
34	Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. American Heart Journal, 2014, 168, 466-470.e1.	2.7	58
35	Frequency of Poor Outcome (Death or Poor Quality of Life) After Left Ventricular Assist Device for Destination Therapy. Circulation: Heart Failure, 2016, 9, .	3.9	54
36	Predictors of Physician Under-Recognition of Angina in Outpatients With Stable Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 554-559.	2.2	53

#	Article	IF	CITATIONS
37	Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. Journal of the American Geriatrics Society, 2018, 66, 1190-1194.	2.6	53
38	Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction. Heart, 2015, 101, 800-807.	2.9	52
39	Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical Care. JAMA Cardiology, 2021, 6, 593.	6.1	50
40	Inclusion of Functional Status MeasuresÂinÂthe Risk Adjustment of 30-Day Mortality After Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2018, 11, 581-589.	2.9	49
41	Development and Application of a Risk Prediction Model for In-Hospital Stroke After Transcatheter Aortic Valve Replacement: AÂReport From The Society of Thoracic Surgeons/American College ofÂCardiology Transcatheter Valve Therapy Registry. Annals of Thoracic Surgery, 2019, 107, 1097-1103.	1.3	49
42	Association of Patient-Reported Health Status With Long-Term Mortality After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, e002875.	3.9	47
43	Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. American Heart Journal, 2016, 175, 94-100.	2.7	47
44	Effects of Ranolazine on Disease-Specific Health Status and Quality of Life Among Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2008, 1, 107-115.	2.2	44
45	Derivation and Validation of a Risk Standardization Model for Benchmarking Hospital Performance for Health-Related Quality of Life Outcomes After Acute Myocardial Infarction. Circulation, 2014, 129, 313-320.	1.6	43
46	Burden of cardioâ€renalâ€metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes, Obesity and Metabolism, 2018, 20, 2000-2003.	4.4	42
47	Psychosocial Modulators of Angina Response to Myocardial Ischemia. Circulation, 2009, 120, 126-133.	1.6	40
48	Incidence and Predictors of Cognitive Decline in Patients with Left Ventricular Assist Devices. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 285-291.	2.2	37
49	Personalizing the Intensity of Blood Pressure Control. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	37
50	Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year. JAMA Cardiology, 2018, 3, 1151.	6.1	36
51	Predicting Quality of Life at 1 Year After Transcatheter Aortic Valve Replacement in a Real-World Population. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004693.	2.2	35
52	Association of Smoking Status With Angina and Health-Related Quality of Life After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 493-500.	2.2	34
53	Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement. Heart, 2015, 101, 1656-1664.	2.9	32
54	Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 208-214.	4.0	32

#	Article	IF	CITATIONS
55	Association Between Cardiac Rehabilitation Participation and Health Status Outcomes After Acute Myocardial Infarction. JAMA Cardiology, 2016, 1, 980.	6.1	31
56	The prevalence and management of angina among patients with chronic coronary artery disease across <scp>US</scp> outpatient cardiology practices: insights from the Angina Prevalence and Provider Evaluation of Angina Relief (<scp>APPEAR</scp>) study. Clinical Cardiology, 2017, 40, 6-10.	1.8	31
57	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes inÂHeartÂFailure With Reduced EjectionÂFraction. JACC: Heart Failure, 2019, 7, 933-941.	4.1	31
58	Prediction of residual angina after percutaneous coronary intervention. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 23-30.	4.0	30
59	Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. American Heart Journal, 2017, 194, 39-48.	2.7	30
60	Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. Diabetes Care, 2016, 39, e99-e101.	8.6	29
61	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). American Heart Journal, 2018, 203, 25-29.	2.7	29
62	Priorities for Patientâ€Centered Research in Valvular Heart Disease: A Report From the National Heart, Lung, and Blood Institute Working Group. Journal of the American Heart Association, 2020, 9, e015975.	3.7	29
63	Impact of short-term complications of transcatheter aortic valve replacement on longer-term outcomes: results from the STS/ACC Transcatheter Valve Therapy Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 208-213.	4.0	29
64	Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocrine Disorders, 2022, 22, 111.	2.2	29
65	In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty. JACC: Cardiovascular Interventions, 2019, 12, 323-331.	2.9	28
66	Composite Metric for Benchmarking Site Performance in Transcatheter Aortic Valve Replacement: Results From the STS/ACC TVT Registry. Circulation, 2021, 144, 186-194.	1.6	26
67	Temporal Trends in Quality of Life Outcomes After Transapical Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 338-346.	2.2	25
68	Validation of the Seattle angina questionnaire in women with ischemic heart disease. American Heart Journal, 2018, 201, 117-123.	2.7	25
69	Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. JACC: Cardiovascular Interventions, 2018, 11, 1188-1198.	2.9	25
70	Health Status Changes and Outcomes inÂPatients With HeartÂFailure and MitralÂRegurgitation. Journal of the American College of Cardiology, 2020, 75, 2099-2106.	2.8	24
71	Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 372-379.	2.2	22
72	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry [®] . Journal of the American Heart Association, 2017, 6, .	3.7	21

#	Article	IF	CITATIONS
73	Dyspnea Among Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	21
74	Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina. JAMA Internal Medicine, 2014, 174, 1403.	5.1	20
75	The Evolution of Patient-Reported Outcomes in Clinical Trials and Management of Patients With Coronary Artery Disease. JAMA Cardiology, 2018, 3, 1035.	6.1	20
76	Association of Changes in HeartÂFailure Treatment With Patients' Health Status. JACC: Heart Failure, 2019, 7, 615-625.	4.1	20
77	Individualizing Revascularization Strategy for Diabetic Patients With MultivesselÂCoronaryÂDisease. Journal of the American College of Cardiology, 2019, 74, 2074-2084.	2.8	19
78	Very Early Changes in Quality of Life After Transcatheter Aortic Valve Replacement: Results From the 3M TAVR Trial. Cardiovascular Revascularization Medicine, 2020, 21, 1573-1578.	0.8	19
79	Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. American Heart Journal, 2014, 168, 457-465.e2.	2.7	17
80	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. Circulation: Heart Failure, 2021, 14, e007564.	3.9	17
81	Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 260-267.	2.2	16
82	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in HeartÂFailure With Secondary MitralÂRegurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2331-2341.	2.9	16
83	The Reliability and Prognosis of In-Hospital Diagnosis of Metabolic Syndrome in the Setting of Acute Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 704-708.	2.8	15
84	Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. European Journal of Preventive Cardiology, 2015, 22, 779-787.	1.8	15
85	Eligibility of patients with type 2 diabetes for sodiumâ€glucose coâ€transporterâ€2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry. Diabetes, Obesity and Metabolism, 2019, 21, 1985-1989.	4.4	15
86	Type of β-blocker use among patients with versus without diabetes after myocardial infarction. American Heart Journal, 2014, 168, 273-279.e1.	2.7	14
87	Precision Medicine for Cardiac Resynchronization. Circulation: Heart Failure, 2017, 10, .	3.9	14
88	Integrating Quality of Life and Survival Outcomes in Cardiovascular Clinical Trials: Results From the PARTNER Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005420.	2.2	14
89	Practical Application of Patient-Reported Health Status Measures for Transcatheter Valve Therapies. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007187.	2.2	14
90	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. American Heart Journal, 2022, 243, 232-239.	2.7	14

#	Article	IF	CITATIONS
91	Impact of Frailty and Prefrailty on Outcomes of Transcatheter or Surgical Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2022, 15, e011375.	3.9	14
92	Hospital-Level Variation in Angina and Mortality at 1 Year After Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 851-856.	2.2	13
93	Global Outcome in Patients With Left Ventricular Assist Devices. American Journal of Cardiology, 2017, 119, 1069-1073.	1.6	13
94	Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. JAMA Network Open, 2020, 3, e203032.	5.9	12
95	Type 2 diabetes and heart failure: insights from the global DISCOVER study. ESC Heart Failure, 2021, 8, 1711-1716.	3.1	10
96	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. BMJ Open Diabetes Research and Care, 2014, 2, e000046.	2.8	9
97	Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. Cardiovascular Revascularization Medicine, 2017, 18, 169-176.	0.8	9
98	Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	9
99	Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010258.	3.9	9
100	Impact of micro―and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study. Endocrinology, Diabetes and Metabolism, 2022, 5, e00321.	2.4	9
101	Implementing an innovative consent form: the PREDICT experience. Implementation Science, 2008, 3, 58.	6.9	8
102	Prognostic Importance of Health Status Versus Functional Status in HeartÂFailure and Secondary Mitral Regurgitation. JACC: Heart Failure, 2021, 9, 684-692.	4.1	8
103	Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 777-784.	2.2	7
104	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. Diabetes, Obesity and Metabolism, 2019, 21, 261-266.	4.4	7
105	Change in Hospitalization Rates Following Transcatheter Mitral Valve Repair. Circulation: Cardiovascular Interventions, 2019, 12, e008342.	3.9	6
106	Prognostic implications of baseline 6â€min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2021, 97, E154-E160.	1.7	6
107	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in HeartÂFailure. JACC: Heart Failure, 2021, 9, 559-567.	4.1	6
108	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: Results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. American Heart Journal, 2015, 170, 753-759.e2.	2.7	5

#	Article	IF	CITATIONS
109	The Impact of Cardiovascular Drugs on Glycemic Control: A Review. Endocrine Practice, 2017, 23, 363-371.	2.1	5
110	Frail Elderly, the Ideal Patients forÂMitraClip. JACC: Cardiovascular Interventions, 2017, 10, 1930-1931.	2.9	5
111	Association Between Diastolic Dysfunction and Health Status Outcomes in PatientsÂUndergoing Transcatheter AorticÂValveÂReplacement. JACC: Cardiovascular Interventions, 2019, 12, 2476-2484.	2.9	5
112	# SoMe for # IC : Optimal use of social media in interventional cardiology. Catheterization and Cardiovascular Interventions, 2021, 98, 97-106.	1.7	5
113	Patient-reported vs. physician-estimated symptoms before and after transcatheter aortic valve replacement. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 161-168.	4.0	5
114	Five-Year Health Status After Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients With Severe Aortic Stenosis. JAMA Cardiology, 2021, 6, 97-101.	6.1	5
115	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPENâ€CTO Registry. Journal of the American Heart Association, 2022, 11, e024056.	3.7	5
116	The Impact of Deâ€escalation of Antianginal Medications on Health Status After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	3.7	4
117	Constraint approaches to the estimation of relative risk. Statistical Methods in Medical Research, 2018, 27, 3436-3446.	1.5	4
118	Association of Smoking Status With Longâ€Term Mortality and Health Status After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Journal of the American Heart Association, 2019, 8, e011766.	3.7	4
119	Anti-anginal medication titration among patients with residual angina 6-months after chronic total occlusion percutaneous coronary intervention: insights from OPEN CTO registry. European Heart Journal Quality of Care & amp; Clinical Outcomes, 2019, 5, 370-379.	4.0	4
120	Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. BMJ Open Diabetes Research and Care, 2021, 9, e001585.	2.8	4
121	The hostile heart: anger as a trigger for acute cardiovascular events. European Heart Journal, 2014, 35, 1359-1360.	2.2	3
122	The Association Between Complementary and Alternative Medicine and Health Status Following Acute Myocardial Infarction. Clinical Cardiology, 2016, 39, 440-445.	1.8	3
123	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications, 2018, 32, 1035-1039.	2.3	3
124	Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry. Cardiovascular Diabetology, 2020, 19, 212.	6.8	3
125	Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. Interactive Journal of Medical Research, 2016, 5, e12.	1.4	3
126	Abstract 11: Comparison of Patient Reported Angina with Provider Assigned Canadian Cardiovascular Society Angina Class Before and After Revascularization. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, .	2.2	3

#	Article	IF	CITATIONS
127	Anxiety and Depression Following Aortic Valve Replacement. Journal of the American Heart Association, 2022, 11, e024377.	3.7	3
128	Realâ€world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "researchâ€ŧoâ€practice―project from the diabetes collaborative registry. Diabetes, Obesity and Metabolism, 2019, 21, 393-396.	4.4	2
129	420-P: Micro- and Macrovascular Events in Patients with T2D—Results from the Global DISCOVER Study. Diabetes, 2019, 68, .	0.6	2
130	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008072.	2.2	2
131	Predicting the Benefit of Statins in Patients With Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 191-193.	2.2	1
132	Goals of Therapy. , 2018, , 227-233.		1
133	De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status. American Heart Journal, 2019, 214, 1-8.	2.7	1
134	Use of non‣DL lipid″owering medications in patients with type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2020, 3, e00126.	2.4	1
135	Can we improve the appropriateness of PCI?. Heart, 2020, 106, 405-406.	2.9	1
136	Incidence, Predictors, and Outcomes of Patients Discharged Home Versus Other Medical Facility After Transcatheter or Surgical Aortic Valve Replacement. Structural Heart, 2021, 5, 392-400.	0.6	1
137	Abstract 13: Patient-reported Health Status Changes are Associated With Subsequent Clinical Outcomes After Transcatheter Valve Therapies: Insights From the Sts/tvt Registry. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, .	2.2	1
138	Impact of Transcatheter Aortic Valve Replacement on Hospitalization Rates: Insights From Nationwide Readmission Database. Journal of the American Heart Association, 2021, 10, e022910.	3.7	1
139	Site-Level Variability in 30-Day Patient Outcomes After Transcatheter Mitral Valve Repair in the United States. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006878.	2.2	Ο
140	Standardizing the standard: reporting health status in clinical trials. European Journal of Heart Failure, 2021, 23, 203-204.	7.1	0
141	Current Indications for Stenting: Symptoms or Survival ^{CME} . Methodist DeBakey Cardiovascular Journal, 2021, 14, 7.	1.0	0
142	Calculating Risk for Poor Outcomes After Transcatheter Aortic Valve Replacement. Journal of Clinical Outcomes Management, 2019, 26, 125-129.	1.7	0